Importantly, the acetylation–autophagy crosstalk itself complicates therapeutic targeting: global HDAC inhibition not only alters histone acetylation but can also reprogram autophagy toward pro-survival functions, while autophagy inhibition may produce opposite outcomes depending on tumor type and disease stage. Here, HDAC9 is linked to neoplasm.